Strong COVID vaccine sales help Moderna beat fourth quarter revenue estimates

The vaccine maker reported fourth-quarter revenue of 678 million dollars today. Strong US sales of its COVID-19 shot helped the company beat analyst targets.

洞察:
Moderna, Inc. reported fourth-quarter revenue of $678 million on February 13, 2026, beating Wall Street estimates of $626.1 million as calculated by LSEG. The quarterly performance was driven in part by stronger-than-expected sales of the company’s COVID-19 vaccine in the US USUS. This revenue beat is significant as the company works to close a revenue gap following the decline in pandemic-era demand for its products.
FILE PHOTO: A sign marks the headquarters of the coronavirus disease (COVID-19) vaccine maker Moderna in Cambridge, Massachusetts, U.S., April 28, 2022. REUTERS/Brian Snyder/File Photo
FILE PHOTO: A sign marks the headquarters of the coronavirus disease (COVID-19) vaccine maker Moderna in Cambridge, Massachusetts, U.S., April 28, 2022. REUTERS/Brian Snyder/File Photo
IUX24

IUX24 提供深度財經、經濟與投資資訊,藉助 AI 發掘全球市場中最重要的信號。

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. 版權所有。

由 AI 驅動 • 精益求精

IUX24 是一個資訊與分析平台,提供新聞、市場數據、分析工具及 AI 驅動的功能,僅供資訊參考與教育用途。所提供的服務和資訊不構成投資建議、交易信號或經紀服務。投資涉及風險,用戶在作出投資決定前應審慎評估相關資訊。